*The US FDA recently extended the DSCSA compliance deadline*
Camber’s Readiness for DSCSA Compliance
Camber is fully prepared to meet the new Drug Supply Chain Security Act (DSCSA) requirements, ensuring enhanced traceability, verification, and safety across the pharmaceutical supply chain. With robust systems for Verification Routing Services, Exception Handling, Master Data Management, and Inventory Control, Camber integrates advanced technology to maintain compliance and uphold the highest product safety standards.
• Status: 100% fully aggregated from bottle to pallet.
• Testing: Completed extensive testing with multiple customers, achieving a 95-100% success rate.
• VRS: Utilizing TraceLink for product authentication since November 2022.
• Handling: Currently conducting EPCIS data testing with all customers.
• GTIN Data: Global Trade Item Numbers are provided to all participating customers via HDAs.
Camber has been fully compliant with the DSCSA requirements since August 2024. However, in October, the FDA granted exemptions from the enhanced drug distribution security requirements for eligible trading partners. These exemptions apply to partners who have completed or made efforts to establish data connections with immediate trading partners but still face challenges in data exchange. The requirements were set to take effect on November 27.
You can learn more about the Drug Supply Chain Security Act (DSCSA) on the FDA’s website.